STTR Phase II: Dendritic Hydrogel Actuators for a Liquid Drug Delivery Patch

STTR 第二阶段：用于液体药物输送贴片的树突状水凝胶致动器

• 批准号: 0848528
• 负责人: Mark Banister
• 金额: $ 50万
• 依托单位: Medipacs Inc
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-01-15 至 2012-12-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=0848528&HistoricalAwards=false
• 关键词: STTR; Phase; II; Dendritic; Hydrogel

This Small Business Technology Transfer Phase II project will develop a class of new, stable, highly responsive Electro Active Polymer (EAP) hydrogel actuator materials. Incorporating dendrimers (dendritic macromolecules) and hyper branched polymers as chemical cross-linking agents into a poly(ethylene glycol) (PEG)-based EAP hydrogel to increase cross-linking densities at low polymer concentration will introduce systematic control of physical properties and performance through structural variables provided by the dendrimer (e.g. generation; end groups; branching ratio; subunit structure). Our research objectives involve the preparation of dendrimer containing PEG hydrogels and the investigation of dendrimer mole fraction, structure, and molecular weight on the stability, strength, physical and responsive properties of the hydrogel material. The new hydrogel actuator materials will enable low cost miniature infusion pump technology. These actuators will be the pump mechanism of a disposable (low cost), small patch like, device being commercialized by Medipacs as the Mini Infuser. The Mini Infuser is a miniature, disposable, programmable drug delivery device designed to significantly lower the cost of patient care while improving a patient's lifestyle with increased pharmacological safety, patient mobility and fewer needle sticks. Medipacs is collaborating with the University of Arizona Chemistry Department to develop the first generation commercial prototype in the Phase II project. Broad application of this technology will impact and lower the cost of healthcare not only for millions of infusion patients but also the industry providers. The projected market in the United States alone is greater than $3 billion. The impact to poorer regions though out the world is immeasurable; life-improving drug therapies such as low cost continuous insulin delivery will be enabled and become available for the first time to patients within these regions.

这个小企业技术转让二期项目将开发一类新的，稳定的，高度响应的电活性聚合物（EAP）水凝胶致动器材料。将树枝状聚合物（树枝状大分子）和超支化聚合物作为化学交联剂分散到基于聚（乙二醇）（PEG）的EAP水凝胶中以在低聚合物浓度下增加交联密度将通过树枝状聚合物提供的结构变量（例如生成;端基;支化比;亚基结构）引入物理性质和性能的系统控制。我们的研究目标包括制备含有PEG的树枝状大分子水凝胶，并研究树枝状大分子的摩尔分数、结构和分子量对水凝胶材料的稳定性、强度、物理和响应性能的影响。新的水凝胶致动器材料将实现低成本微型输液泵技术。这些致动器将是一次性（低成本）、小贴片状装置的泵机构，Medipacs正在将其作为迷你输注器进行商业化。 迷你输液器是一种微型、一次性、可编程药物输送装置，旨在显著降低患者护理成本，同时改善患者的生活方式，提高药理安全性、患者移动性和减少针刺。Medipacs正在与亚利桑那大学化学系合作，在第二阶段项目中开发第一代商业原型。这项技术的广泛应用将影响和降低医疗保健成本，不仅为数百万输液患者，而且也为行业提供者。仅在美国的预计市场就超过30亿美元。对世界上较贫困地区的影响是不可估量的;改善生活的药物治疗，如低成本的连续胰岛素输注，将首次在这些地区的患者中实现并提供。